Skip to main content

Table 2 Characteristics and data of high-risk patients in the initial treatment (IVIG+steroid)-responsive and initial treatment-resistant groups

From: Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study

  IVIG +steroid responder group IVIG +steroid resistant group p-value
Number 27 10  
Age (months) 42 [11–80] 44 [9–86] 0.880
Male gender, n (%) 17 (63.0) 8 (80.0) 0.285
Illness day at diagnosis 4 [2–8] 3 [2–7] 0.220
Kobayashi score 6 [5–10] 6 [5–10] 0.216
< Laboratory data before 1st line therapy >
TN-C, ng/mL 117.6 [35.0–324.8] 175.8 [80.4–380.9] 0.037
WBC, × 103/μL 14.8 [6.6–33.2] 18.6 [6.9–36.8] 0.242
Neutrophils, % 83 [60–95] 88 [68–94] 0.191
Platelets, × 104/mL 26.2 [13.1–59.4] 23.9 [13.5–36.6] 0.555
CRP, mg/dL 10.0 [2.5–24.0] 10.1 [5.2–21.7] 0.853
Albumin, g/dL 3.6 [2.7–4.1] 3.6 [2.8–4.4] 0.801
T-bilirubin, mg/dL 0.7 [0.3–5.5] 1.4 [0.5–4.6] 0.391
AST, IU/L 57 [20–787] 551 [25–2725] 0.013
ALT, IU/L 83 [8–937] 518 [9–1435] 0.067
Sodium, mEq/L 133 [127–137] 132 [128–135] 0.578
  1. TN-C tenascin-C, WBC white blood cell, CRP C-reactive protein, AST aspartate aminotransferase, ALT alanine aminotransferase
  2. * The Kobayashi score [8] was ≥5 points in all cases
  3. * In all cases, the first-line therapy was IVIG, prednisolone, and aspirin